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Abstract
Background: Loss of PTEN is a common genomic aberration in castration-resistant
prostate cancer (CRPC) and is frequently concurrent with ERG rearrangements, causing
resistance to next-generation hormonal treatment (NGHT) including abiraterone. The
relationship between PTEN loss and docetaxel sensitivity remains uncertain.
Objective: To study the antitumor activity of docetaxel in metastatic CRPC in relation
to PTEN and ERG aberrations.
Design, setting, and participants: Single-centre, retrospective analysis of PTEN loss and
ERG expression using a previously described immunohistochemistry (IHC) binary
classiﬁcation system. Patients received docetaxel between January 1, 2006 and July 31,
2016.
Outcome measurements and statistical analysis: Response correlations were analyzed
using Pearson’sx2 tests and independent-sample t tests. Overall (OS) and progression-
free survival (PFS) were analyzed using univariate and multivariate (MVA) Cox
regression and Kaplan-Meier methods.
Results and limitations: Overall, 215 patients were eligible. Established metastatic
CRPC prognostic factors were well balanced between PTEN loss (39%) and normal
patients (61%). PTEN loss was associated with shorter median OS (25.4 vs 34.7 mo;
hazard ratio [HR] 1.66, 95% conﬁdence interval [CI] 1.18–2.13; p = 0.001). There were
no differences in median PFS (8.0 vs 9.1 mo; univariate HR 1.20, 95% CI 0.86–1.68;
p = 0.28) and PSA response (53.4% vs 50.6%; p = 0.74). PTEN loss was an independent
prognostics factor in MVA. ERG status was available for 100 patients. ERG positivity
was not associated with OS or PFS. Limitations include the retrospective nature and
the single-centre analysis.
Conclusions: Our ﬁndings suggest that metastatic CRPC with PTEN loss might beneﬁt
more from docetaxel than from NGHT.
Patient summary: In this study we found that metastatic prostate cancer with loss of
the PTEN switch may beneﬁt more from docetaxel than from abiraterone.
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Prostate cancer (PC) is the most common malignancy in
men and a common cause of cancer-related death in
Western countries [1]. Molecular characterization of
metastatic castration-resistant PC (mCRPC) through
whole-exome and transcriptome sequencing has offered
an insightful understanding of its biology, identifying
aberrations of the androgen receptor (AR); gene fusions
including those involving TMPRSS2 and ERG; and PTEN loss,
commonly via deletion [2].
PTEN acts as a phosphatase regulator of the PI3K/AKT
pathway, which is also involved in regulating AR signaling
and in hormonal resistance in preclinical models [3]. PTEN
loss is an early and stable event in the carcinogenesis
process and is associated with poor prognosis [4–7] and
short response to next-generation hormonal treatment
(NGHT) such as abiraterone acetate (AA) [8]. This has
prompted investigators to design studies evaluating the
efficacy of the combination of NGHT and PI3K/AKT
inhibitors [9,10].
The impact of PTEN loss, which commonly co-occurs
with ERG genomic rearrangements, on the taxane sensitivi-
ty of mCRPC has not yet been clearly elucidated. Therefore,
in this retrospective study we investigated PTEN protein
expression in both hormone-naïve PC and mCRPC samples
from patients with advanced disease and evaluated clinical
outcomes and the association of docetaxel response with
PTEN status. We then analyzed the association of PTEN loss
and ERG expression and retrospectively evaluated the
impact of high ERG expression on outcome from docetaxel
in this cohort of patients.
2. Patients and methods
2.1. Patient cohort
Potentially eligible cases were identiﬁed from a population of men
with mCRPC treated at the Royal Marsden NHS Foundation Trust
between January 2006 and July 2016. Patients were included in
the study if they had received docetaxel treatment for mCRPC (either
as ﬁrst-line treatment or after NGHT) and had parafﬁn tissue blocks
from metastatic sites or diagnostic samples for PTEN immunohis-
tochemistry (IHC) available. Exclusion criteria were previous treat-
ment with a PI3K/AKT inhibitor and histologic features of
neuroendocrine or small cell cancer. All patients gave their written
informed consent and were enrolled in institutional protocols
approved by the Royal Marsden NHS Foundation Trust Hospital
ethics review committee (reference no. 04/Q0801/60). Demographic
and clinical data were retrospectively collected using the hospital
electronic patient record system.
2.2. Tissue samples
PC tissue was obtained from prostate needle biopsies, transurethral
resections of the prostate, prostatectomies, or PC metastases at the time
of castration resistance within bone (bone marrow trephine), lymph
nodes, or viscera (needle biopsies). All tissue blocks were sectioned and
reviewed by a pathologist (D.N.R.) for conﬁrmation of the adequacy of
the material (>50 viable cells).2.3. PTEN IHC
PTEN protein expression was determined via IHC on 4-mm-thick
formalin-ﬁxed, parafﬁn-embedded sections as previously described
[11,12]. In brief, PTEN immunoreactivity was investigated using rabbit
monoclonal anti-PTEN antibody 138G6 (Cell Signaling Technology,
Danvers, MA, USA) [13] and detected using a Vectastain Elite ABC kit
(Vector Laboratories, Burlingame, CA, USA). The intensity of nuclear and
cytoplasmic staining was semiquantitatively assessed using the H-score
formula as previously deﬁned [8]. PTEN-positive controls included
normal prostate tissue and 22RV1 xenograft tissue, and PTEN-loss
controls included PC3 (PTEN-null PC cell line) xenografts. Endothelial
cells and stroma were used as internal positive controls for PTEN. A
binary classiﬁcationwas used for IHC PTEN positivity or loss according to
validation studies previously published by our group [8]. Cases were
considered PTEN-negative if they either showed a complete absence of
PTEN staining or weak-intensity staining compared to the internal
control in no more than 10% of cancer cells (H-score >10). All IHC
sections were evaluated by a pathologist (D.N.R.) blinded to the patients’
clinical characteristics and outcome data.
A small fraction of tumors showed prominent intratumor heteroge-
neity for PTEN expression with clearly distinct PTEN-positive and PTEN-
negative areas, suggesting two clear populations of tumor cells in which
one population had PTEN loss and the other did not. For the purpose of
this data analysis, a casewas considered PTEN-negative if any tumor area
showed a complete absence of PTEN staining. For the survival analyses,
when a change in PTEN status was observed between patient-matched
hormone-naïve PC and CRPC samples, cases were classiﬁed according to
the PTEN status in the CRPC sample.
2.4. ERG IHC
Antigen retrieval was conducted by heating slides in Tris-EDTA buffer
(pH 8.1) using amicrowave. Protein blockingwas performed to eliminate
nonspeciﬁc background staining using serum-free protein block #X0909
(Dako, Glostrup, Denmark). The primary antibody was #ab92513 from
Abcam (Cambridge, UK) diluted 1:200 in Dako antibody diluent. The
detection kit was a REAL EnVision detection system and DAB reagent
(Dako). A negative control serum (rabbit IgG control antibody I-1000;
Vector Laboratories) was used instead of the primary antibody for the
negative controls. Control sections included a VCaP xenograft, a PC3
xenograft, and normal prostate tissue. Caseswere scored by a pathologist
(D.N.R) blinded to clinical data using a modiﬁed H-score (HS) method,
which is a semiquantitative assessment of staining intensity that reﬂects
antigen concentration. HS was determined according to the formula [(%
of weak staining)  1] + [(% of moderate staining)  2] + [(% of strong
staining)  3], yielding a range from 0 to 300.
2.5. Statistical analysis
Biochemical response to docetaxel was deﬁned according to Prostate
Cancer Working Group Criteria 3 as a 30% decline in prostate-speciﬁc
antigen (PSA) from baseline, conﬁrmed at least 3 wk later [14]. Survival
was measured from the ﬁrst date of docetaxel treatment to the date of
last contact or the date of death fromany cause. Progression-free survival
(PFS) was deﬁned as the time from docetaxel initiation to the time of
progression during or beyond the discontinuation of docetaxel because
of radiological and/or biochemical progression or death. In patients with
measurable disease on computed tomography imaging, the radiographic
response was also assessed according to Response Evaluation Criteria in
Solid Tumors (RECIST) v.1.1 [15]. The Kaplan-Meier product limit method
was used to estimate the duration of docetaxel treatment, PFS, and
overall survival (OS) by PTEN status. Independent-sample t tests and
Pearson’s x2 tests were used to investigate the association of PTEN loss
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two-sided, and p  0.05 was considered statistically signiﬁcant.
Approximately 50% of patients were missing one or more indepen-
dent factors at baseline, 30% of patients were missing values for all
laboratorymeasurements. These valueswere considered to bemissing at
random from clinical notes and it was thought to be unlikely that there
were systematic differences between the missing and observed values.
To avoid a loss in precision, multiple imputation by chained equations
was conducted using baseline patient and tumor characteristics. PTEN
status and visceral disease were completely observed and were included
in the imputation model with the Nelson-Aalen estimate and censoring
indicators for mortality or progression depending upon the analysis.
ECOG performance status1, Gleason score8 and previous experience
of AA were imputed using logistic regression models; albumin, log10
alkaline phosphatase, hemoglobin, log10 neutrophil to lymphocyte ratio
and log10 lactate dehydrogenase were imputed using linear regression
models which assumed normality. In total, after a 100 imputation burn-
in, 50 imputations were used and results were combined using Rubin’s
rules. Univariate and multivariate analyses of PTEN status, ERG status
and other potential independent factors for OS, duration of docetaxel
treatment and PFS were performed using the Cox regression model
with a 95% conﬁdence interval (CI). Descriptive statistics and survival
analyses were performed using Stata v13.1 (Stata Corp., College Station,
TX, USA).
3. Results
3.1. Tissue samples and patient characteristics
We identified 215 patients who received treatment with
docetaxel and had tissue available for PTEN analysis. A
single tissue sample was available for 160 patients, while
55 patients had matched samples collected at the time of
diagnosis and in the castration-resistant phase. A total of
270 samples were scored for PTEN by IHC. Intrapatient
concordance was present in 87% of the matched samples
(48 of 55) with a change in PTEN status observed in only
seven of 55 patients (13%). Overall, PTEN loss was
demonstrated in 83 of the 215 patients (39%).
Key baseline patient characteristics are listed in
Table 1. Patients received a median of eight cycles of
docetaxel, with median treatment duration of 5.1 mo. There
were no significant differences in hemoglobin, albumin,
lactate dehydrogenase, neutrophil/lymphocyte ratio, or
performance status between PTEN-loss and PTEN-positive
patients before docetaxel initiation; only alkaline phospha-
tase levels were higher in PTEN-loss patients (p = 0.02).
Globally, 33 patients (15.4%) had visceral metastases at
docetaxel initiation, with no significant difference between
the groups (14.5% vs 15.9%; p = 0.77).
3.2. Outcomes
Median OS from the start of docetaxel treatment for the
whole cohort was 29.3 mo (95% confidence interval [CI]
26.6–35.1); 180 patients (83.7%) had died by the time of data
cutoff. Median PFS was 8.9 mo (95% CI 8.1–10.3). Patients
with PTEN loss had worse OS than patients with normal
PTEN expression (25.4 vs 34.7 mo; univariate hazard ratio
[HR] 1.66, 95% CI 1.23–2.24; p = 0.001; Fig. 1) in both
univariable and multivariable (MVA) Cox regressionanalyses (Table 2). PTEN loss, higher lactate dehydrogenase
levels, and lower albumin remained strongly associated
with worse OS in MVA (p < 0.05).
There was no difference in PFS observed between
patients whose tumors had PTEN loss and those with
PTEN-positive disease (median 8.0 vs 9.1 mo; HR 1.20, 95%
CI 0.86–1.68; p = 0.28; Fig. 1B, Supplementary Table 1), with
a similar median number of docetaxel cycles (7.5 vs 8.0;
p = 0.29) andmedian time on docetaxel (5.0mo [95% CI 4.2–
5.5] vs 5.2mo [95% CI 4.7–6.0]; p = 0.23). Overall, 86 patients
(40.1%) received further treatment with cabazitaxel; of
these, 56 (65.1%) had tumors with PTEN loss.
Data on PSA responsewere available for 143 patients. The
overall median PSA decline was 53.3% (95% CI 61.7% to
42.9%); 74 of the 143 patients (51.8%) experienced a PSA
response. Patients receiving docetaxel as first-line therapy
for mCRPC were more likely to experience a PSA response
than those receiving second-line docetaxel (58.4% vs 38.5%;
p = 0.03). There was no difference in PSA response rate
between patients with and without PTEN loss (53.5% vs
50.6%; p = 0.795; Fig. 2). Furthermore, 128 patients (59.5%)
had scans available for assessment of radiological response.
Of these 128, 55 patients (43.0%) had bone-only disease and
73 (57.0%) had measurable disease by RECIST. Among the
latter 73 evaluable patients, 23 (31.5%) had a partial response
during docetaxel treatment or at treatment completion.
Response rates were not different between PTEN-loss and
PTEN-positive mCRPC (28.6% vs 33.3%; p = 0.67; Table 3).
3.3. ERG status and correlation with outcome
To further characterize this mCRPC population, we evaluat-
ed ERG status in 100 tumors. IHC revealed 58 tumors (58%)
with ERG-negative status and 42 (42%) with ERG positivity.
ERG status was consistent between matched hormone-
naïve and CRPC samples from the same patient, with only
one patient having discordant hormone-naïve and CRPC
ERG staining. There was a significant association between
ERG-positive staining and PTEN loss (Fisher’s exact test,
p = 0.02; Supplementary Table 2). Despite this, no difference
was observed in terms of OS (univariate HR 0.94, 95% CI
0.60–1.47; p = 0.79), PFS (HR 1.08, 95% CI 0.65–1.77;
p = 0.77), and time on docetaxel (HR 1.06, 95% CI 0.70–
1.58; p = 0.79) when patients were dichotomized according
to ERG tumor status (Supplementary Figs. 1–3). In the
subgroup with known ERG status, PTEN loss remained
associated with worse survival (univariate HR 1.62, 95% CI
1.20–2.18; p = 0.002).4. Discussion
Hyperactivation of the PI3K/AKT/mTOR pathway, generally
through loss of PTEN function, is one of the most common
aberrations driving progression in mCRPC [2]. PTEN loss of
function can be due to different genomic (deletion,
microdeletions, and rearrangements, including intronic
rearrangements) and nongenomic mechanisms (methyla-
tion, miRNA, pseudo-gene expression) [2]. At the post-
Table 1 – Patient characteristics at baseline.
Overall PTEN-positive PTEN loss p value
Patients (n) 215 132 83
Median age, yr (IQR) 70 (66–75) 68 (63–73) 66 (61–72) 0.23
Gleason score at diagnosis, n (%) 0.66
6 17 (7.9) 10 (7.6) 7 (8.4)
7 51 (23.7) 28 (21.2) 23 (27.7)
8–10 113 (52.6) 71 (53.8) 42 (50.6)
Missing 34 (15.8) 23 (17.4) 11 (13.3)
Sites of metastases at start of DTX, n (%) 0.78
Bone only 84 (39.1) 48 (36.4) 36 (43.4)
Nodal 63 (29.3) 40 (30.3) 23 (27.7)
Visceral 33 (15.4) 21 (15.9) 12 (14.5)
Missing 35 (16.3) 23 (17.4) 12 (14.5)
ECOG performance status, n (%) 0.46
0 78 (36.3) 30 (36.1) 48 (36.4)
1 78 (36.3) 33 (39.8) 45 (34.1)
2 5 (2.3) 3 (3.6) 2 (1.5)
Missing 54 (25.1) 17 (20.5) 37 (28.0)
Prostate-speciﬁc antigen 0.15
Median, ng/ml (IQR) 116 (47–404) 139 (58–569) 109 (32–369)
Missing, n (%) 59 (27.4) 39 (29.6) 20 (24.1)
Hemoglobin 0.81
Median, g/dl (IQR) 12 (11–13) 12 (11–13) 12 (11–13)
Missing, n (%) 80 (37.2) 53 (40.2) 27 (32.5)
Alkaline phosphatase 0.02
Median, IU/l (IQR) 127 (76–259) 116 (72–203) 211 (81–435)
Missing, n (%) 79 (36.7) 52 (39.4) 27 (32.5)
Lactate dehydrogenase 0.35
Median, IU/l (IQR) 192 (149–239) 188 (146–239) 197 (156–245)
Missing, n (%) 84 (39.1) 56 (42.4) 28 (33.7)
Albumin 0.19
Median, g/l (IQR) 36 (32–38) 36 (33–39) 35 (32–38)
Missing, n (%) 80 (37.2) 53 (40.2) 27 (32.5)
Neutrophils 0.99
Median (IQR) 4.6 (3.5–6.8) 4.6 (3.6–6.9) 4.5 (3.3–6.9)
Missing, n (%) 81 (37.7) 54 (40.9) 27 (32.5)
Lymphocytes 0.72
Median (IQR) 1.2 (0.8–1.6) 1.2 (0.8–1.6) 1.1 (0.8–1.7)
Missing, n (%) 81 (37.7) 54 (40.9) 27 (32.5)
Neutrophil/lymphocyte ratio 0.65
Median (IQR) 4.0 (2.5–8.8) 4.0 (2.4–9.0) 4.0 (2.4–8.6)
Missing, n (%) 81 (37.7) 54 (40.9) 27 (32.5)
Previous abiraterone, n (%) 0.69
Yes 51 (23.7) 31 (23.5) 20 (24.1)
No 159 (74.0) 97 (73.5) 62 (74.7)
Missing 5 (2.3) 4 (3.0) 1 (1.2)
IQR = interquartile range; DTX = docetaxel; ECOG = Eastern Cooperative Oncology Group.
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modifications, including phosphorylation, oxidation, and
ubiquitination, with intrapatient heterogeneity in approxi-
mately 10% of cases [16,17].
PTEN loss results in hyperactivation of the PI3K/AKT/
mTOR pathway, which in turn is highly related to the activity
of the AR pathway [3]. While PI3K/AKT/mTOR activation can
suppress AR transcriptional output and stability [18], PI3K/
AKT/mTOR signaling is activated following androgen depri-
vation, especially in patients with PTEN loss [19].
In the present analysis for patients treated with
docetaxel, we confirmed the prognostic importance of
PTEN loss in mCRPC. However, we found no evidence that
docetaxel antitumor activity is impaired in PTEN-loss
mCRPC, with no difference in the number of cycles
administered, the duration of docetaxel treatment, or thePSA or RECIST response between PTEN-loss and PTEN-
positive tumors. However, thismay not be the case in earlier
stages of the disease, as PTEN loss was associated with
shorter PFS among 57 patients treated on a trial of adjuvant
docetaxel after radical prostatectomy [20].
In this study, in the PTEN-positive group, 31 patients
(23.5%) received AA before chemotherapy and 97 patients
(73.5%) received AA after chemotherapy. In the PTEN-loss
group, 20 patients (24.1%) received AA before docetaxel and
62 patients (74.7%) received AA after docetaxel (Table 1).
Therefore, the two groups were well balanced in term of
anticancer treatments. We previously showed that AA has
lower antitumor activity against PTEN-loss tumors [8],
which might explain why patients with PTEN-loss tumors
experience shorter OS despite no difference in term of PFS
on docetaxel.
[(Fig._1)TD$FIG]
Fig. 1 – Kaplan-Meier curves for (A) median overall survival (OS) and (B) median progression-free survival (PFS) from the start of docetaxel
chemotherapy for patients with PTEN loss and those with PTEN-positive tumors. CI = confidence interval; DTX = docetaxel.
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AA + ipatasertib/placebo in which patients with PTEN-loss
tumors in the AA + placebo arm had significantly shorter
radiographic PFS when compared to the PTEN-positive
group. Conversely, co-targeting of AR and AKT using AA
+ ipatasertib in combination improved outcomes compared
to AA alone in PTEN-loss cancers [9]. Taken together, these
data suggest that docetaxel might be a preferable option for
this patient population.
As mCRPCs with PTEN deletion are enriched in ERG
genomic rearrangements [21],with PTEN loss postulated as
being a later event to ERG rearrangements [22], weTable 2 – Univariable and multivariable Cox regression analyses for
overall survival.
Univariable Multivariable
HR (95% CI) p value HR (95% CI) p value
PTEN status (loss) 1.66 (1.23–2.34) 0.001 1.73 (1.21–2.46) 0.003
Previous abiraterone 1.52 (1.06–2.17) 0.02 1.40 (0.90–2.18) 0.13
Hemoglobin (g/dl) 1.00 (0.97–1.03) 0.94 – –
Albumin (g/l) 0.92 (0.87–0.97) 0.002 0.94 (0.88–1.00) 0.05
ALP (log10 IU/l) 2.02 (1.14–3.58) 0.02 1.11 (0.59–2.11) 0.73
LDH (log10 IU/l) 5.33 (1.39–20.49) 0.02 4.78 (1.33–17.22) 0.02
NLR (log10) 1.09 (0.78–1.52) 0.62 – –
ECOG PS 1 1.74 (1.23–2.46) 0.001 1.45 (0.94–2.24) 0.09
Gleason score 8 1.43 (1.02–2.00) 0.04 1.37 (0.93–2.02) 0.11
Visceral disease 1.65 (1.10–2.46) 0.01 1.57 (0.97–2.53) 0.07
HR = hazard ratio; CI = conﬁdence interval; ECOG PS = Eastern Cooperative
Oncology Group performance status; PSA = prostate-speciﬁc antigen;
ALP = alkaline phosphatase; LDH = lactate dehydrogenase;
NLR = neutrophil/lymphocyte ratio.analyzed ERG status in the tumors from 100 patients in
this cohort. Gene fusions involving TMPRSS2 and ERG can
be detected by IHC and/or fluorescent in situ hybridization
(FISH), and are common in PC (30–50%) [23], being highly
associated with ERG protein overexpression [24]. The role
of these ERG rearrangements in prognosis and survival
remains controversial, although a recent meta-analysis of
5074 men treated with radical prostatectomy revealed no
association between ERG rearrangements and clinical
outcome [25–28]. A recent study evaluating ERG rearran-
gements in peripheral blood mononuclear cells using
quantitative reverse transcription polymerase chain[(Fig._2)TD$FIG]
Fig. 2 – Waterfall plot of prostate-specific antigen (PSA) change for
patients with PTEN loss and those still PTEN-positive. The bar indicates
a 30% decline in PSA from baseline.
Table 3 – PSA and RECIST responses to treatment.
Patients, n (%) p value
Total PTEN-positive PTEN loss
PSA response a 74 (51.8) 43 (50.6) 31 (53.5) 0.74
No PSA response 69 (48.3) 42 (49.4) 27 (46.6)
RECIST response (PR) 23 (31.5) 15 (33.3) 8 (28.6) 0.67
No RECIST response
(SD or PD)
50 (68.5) 30 (66.7) 20 (71.4)
PSA = prostate-speciﬁc antigen; RECIST = Response Evaluation Criteria in
Solid Tumors; PR = partial response; SD = stable disease; PD = progressive
disease.
a A PSA response was defined as a 30% PSA decline from baseline.
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with taxane resistance in mCRPC. However, the incidence
of ERG rearrangements detected with this method
appeared to be particularly low (16%) compared to IHC
and FISH tumor tissue–based testing [29]. Our analyses
confirm that ERG positivity is a common event in PC and
correlates with PTEN loss; however, we found no associa-
tion between ERG status and clinical outcome from or
response to docetaxel in mCRPC. Moreover, ERG status was
not prognostic in our population.
4.1. Limitations
Patients in this study came from a single centre, so these
findings may not be generalizable to patients treated at
other institutions and require prospective confirmation
through a multicenter study. Furthermore, the patient
cohort was retrospectively collected and so could suffer
from selection bias.
5. Conclusions
Wehave shown for the first time and in the largest series on
PTEN loss reported to date that despite being a prognostic
factor, independent of ERG status, PTEN loss does not alter
response to taxane-based chemotherapy. We envision that
these findings may be relevant to treatment selection.
Prospective trials are warranted to determine whether
mCRPC patients with PTEN loss might be better served by
docetaxel treatment rather than NGHT.
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